Published in Br J Cancer on February 14, 2005
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol (2011) 4.66
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet (2008) 2.77
Global magnitude of reported and unreported mesothelioma. Environ Health Perspect (2011) 2.27
Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer (2009) 2.18
Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ (2011) 2.16
Occupation and cancer in Britain. Br J Cancer (2010) 1.83
Work-related mortality in England and Wales, 1979-2000. Occup Environ Med (2010) 1.82
Malignant mesothelioma. Orphanet J Rare Dis (2008) 1.80
The case for a global ban on asbestos. Environ Health Perspect (2010) 1.73
Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg (2012) 1.67
BTS statement on malignant mesothelioma in the UK, 2007. Thorax (2007) 1.51
Filing for workers' compensation among Ontario cases of mesothelioma. Can Respir J (2009) 1.47
Projected mesothelioma incidence in men in New South Wales. Occup Environ Med (2007) 1.20
Projection of mesothelioma mortality in Britain using Bayesian methods. Br J Cancer (2010) 1.11
Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma. J Cancer Res Clin Oncol (2013) 1.00
A short history of the toxicology of inhaled particles. Part Fibre Toxicol (2012) 0.95
Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol (2016) 0.95
Pleural mesothelioma presenting as periumbilical metastasis: the first clinical documentation. Case Rep Oncol Med (2013) 0.95
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer (2008) 0.94
Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients. Radiol Oncol (2012) 0.92
Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol (2011) 0.91
Malignant pleural mesothelioma: current and future perspectives. J Thorac Dis (2013) 0.91
Pleural controversies: image guided biopsy vs. thoracoscopy for undiagnosed pleural effusions? J Thorac Dis (2015) 0.91
Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer (2011) 0.91
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer (2011) 0.91
Long-term Realism and Cost-effectiveness: Primary Prevention in Combatting Cancer and Associated Inequalities Worldwide. J Natl Cancer Inst (2015) 0.90
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. Br J Cancer (2014) 0.90
The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma. Br J Cancer (2013) 0.88
Pleural cancer mortality in Spain: time-trends and updating of predictions up to 2020. BMC Cancer (2013) 0.88
Certified causes of death in patients with mesothelioma in South East England. BMC Cancer (2009) 0.87
The health impact of nonoccupational exposure to asbestos: what do we know? Eur J Cancer Prev (2009) 0.87
The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. Br J Cancer (2010) 0.86
Telomerase activity in pleural malignant mesotheliomas. Lung Cancer (2011) 0.86
A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. BMC Cancer (2014) 0.83
Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position. Thorax (2013) 0.82
Towards elimination of asbestos-related diseases: a theoretical basis for international cooperation. Saf Health Work (2010) 0.81
Mesothelioma: time to take stock. J R Soc Med (2005) 0.80
Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers. Oncotarget (2016) 0.79
Malignant pleural mesothelioma: a single-center experience in Turkey. Med Sci Monit (2014) 0.79
Prediction of mesothelioma and lung cancer in a cohort of asbestos exposed workers. Eur J Epidemiol (2008) 0.79
Simultaneous bilateral spontaneous hydropneumothorax: a rare presentation of bilateral malignant pleural mesothelioma. BMJ Case Rep (2013) 0.79
Incidence of mesothelioma in Lombardy, Italy: exposure to asbestos, time patterns and future projections. Occup Environ Med (2016) 0.78
SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma. Cell Death Dis (2013) 0.78
Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma? Ther Clin Risk Manag (2016) 0.77
Association of biomarker levels with severity of asbestos-related diseases. Saf Health Work (2012) 0.77
Advances in malignant peritoneal mesothelioma. Int J Colorectal Dis (2014) 0.76
Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis. PLoS One (2014) 0.76
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). BMC Cancer (2015) 0.75
Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry? Front Genet (2014) 0.75
Radiologic Diagnosis of Asbestosis in Korea. Korean J Radiol (2016) 0.75
Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma. Dis Markers (2017) 0.75
Coarse pleural calcification in a mesothelioma patient raises the possibility of a rare tumour subtype: osteoblastic sarcomatoid mesothelioma. Br J Radiol (2011) 0.75
Awareness of Asbestos and Action Plans for Its Exposure can Help Lives Exposed to Asbestos. Saf Health Work (2013) 0.75
Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma. Clin Lung Cancer (2016) 0.75
Occupational cancer in Britain. Preventing occupational cancer. Br J Cancer (2012) 0.75
Estimated future incidence of malignant mesothelioma in South Korea: Projection from 2014 to 2033. PLoS One (2017) 0.75
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). Cancers (Basel) (2017) 0.75
Continuing increase in mesothelioma mortality in Britain. Lancet (1995) 6.78
The European mesothelioma epidemic. Br J Cancer (1999) 6.28
Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment. Br J Cancer (1982) 3.61
Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol (2004) 3.28
Mesothelioma register 1967-68. Br J Ind Med (1974) 2.42
Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health (2003) 1.70
Update of predictions of mortality from pleural mesothelioma in the Netherlands. Occup Environ Med (2003) 1.58
Prediction of mesothelioma, lung cancer, and asbestosis in former Wittenoom asbestos workers. Br J Ind Med (1991) 1.51
Pleural mesothelioma in Sweden: an analysis of the incidence according to the use of asbestos. Occup Environ Med (1999) 1.48
Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev (1997) 1.43
Dose-response relationships for asbestos-related disease: implications for hygiene standards. Part II. Mortality. Ann N Y Acad Sci (1979) 1.36
Estimation of the past and future burden of mortality from mesothelioma in France. Occup Environ Med (1998) 1.26
Incidence rates of malignant mesothelioma in Denmark and predicted future number of cases among men. Scand J Work Environ Health (2000) 1.16
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer (1977) 53.23
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer (1976) 22.55
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst (1995) 18.86
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med (1991) 12.89
Cohort study analysis with a FORTRAN computer program. Int J Epidemiol (1986) 6.66
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J (1979) 5.58
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer (2002) 4.18
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet (1995) 3.71
Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment. Br J Cancer (1982) 3.61
Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. Lancet (1993) 2.58
Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol (1997) 2.40
Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer (2006) 2.27
A population-based approach to diabetes management in a primary care setting: early results and lessons learned. Eff Clin Pract (1999) 2.26
Cyclic oscillations of basal plasma glucose and insulin concentrations in human beings. N Engl J Med (1979) 2.25
High-resolution computed tomography of the basilar artery: 2. Vertebrobasilar dolichoectasia: clinical-pathologic correlation and review. AJNR Am J Neuroradiol (1986) 2.25
Price and consumption of cigarettes: a case for intervention? Br J Prev Soc Med (1974) 2.22
Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer (2009) 2.18
Spontaneous abortion in the British semiconductor industry: An HSE investigation. Health and Safety Executive. Am J Ind Med (1999) 2.10
Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children. Chest (2001) 2.09
Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism (1979) 2.07
Prospective study of cancer in patients with hypogammaglobulinaemia. Lancet (1985) 2.03
The hygiene standard for chrysotile asbestos. Lancet (1978) 2.02
HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer (2006) 1.99
Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. IARC Monogr Eval Carcinog Risk Chem Hum Suppl (1980) 1.99
National study of colorectal cancer genetics. Br J Cancer (2007) 1.92
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis. Br J Haematol (1981) 1.83
Relationship of mortality to measures of environmental asbestos pollution in an asbestos textile factory. Ann Occup Hyg (1985) 1.83
An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer (1990) 1.83
Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer (2008) 1.77
Completeness of cancer registration: a new method for routine use. Br J Cancer (2000) 1.75
Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer (2000) 1.74
Rebuttal from the Health and Safety Executive. Int J Occup Environ Health (2000) 1.71
Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). Br J Haematol (1991) 1.70
A mortality study among workers in an English asbestos factory. Br J Ind Med (1977) 1.69
HIV testing on all pregnant women. Lancet (1987) 1.66
An update of cancer mortality among chrysotile asbestos miners in Balangero, northern Italy. Br J Ind Med (1990) 1.65
Intratype variation in 12 human papillomavirus types: a worldwide perspective. J Virol (1996) 1.65
That the effects of smoking should be measured in pack-years: misconceptions 4. Br J Cancer (2012) 1.63
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res (2000) 1.62
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet (1997) 1.55
Systolic blood pressure variation during the first 6 days of life. Clin Sci Mol Med (1975) 1.52
ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess (2009) 1.51
Lung cancer mortality in relation to measured dust levels in an asbestos textile factory. IARC Sci Publ (1980) 1.48
Day care in infancy and risk of childhood acute lymphoblastic leukaemia: findings from UK case-control study. BMJ (2005) 1.48
MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J (1978) 1.46
Persisting risk of nickel related lung cancer and nasal cancer among Clydach refiners. Occup Environ Med (2006) 1.42
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene (1998) 1.41
A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer (2005) 1.40
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
Familiarisation to and reproducibility of cycling at 110% peak power output. J Sports Med Phys Fitness (2014) 1.39
Tuberculosis in Scotland: a national sample survey (1968-70). 2. A two-year follow-up of newly-diagnosed respiratory tuberculosis notified in 1968. Tubercle (1976) 1.39
Retracted High rate of human papillomavirus type 16 infection in cytologically normal cervices. Lancet (1989) 1.38
Inherited susceptibility to breast cancer. Cancer Surv (1993) 1.36
Dose-response relationships for asbestos-related disease: implications for hygiene standards. Part II. Mortality. Ann N Y Acad Sci (1979) 1.36
Life events and psychiatric disorders. 2. Nature of causal link. Psychol Med (1973) 1.36
The contribution of inherited predisposition to cancer incidence. Cancer Surv (1990) 1.35
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Models for respiratory cancer in nickel refinery workers. J Natl Cancer Inst (1986) 1.30
Genetic heterogeneity and localization of a familial breast-ovarian cancer gene on chromosome 17q12-q21. Am J Hum Genet (1993) 1.29
Cancers of the respiratory tract in mustard gas workers. Br J Ind Med (1988) 1.28
Body fatness and physical activity at young ages and the risk of breast cancer in premenopausal women. Br J Cancer (2005) 1.26
Pulmonary tuberculosis in Scotland: a national sample survey and follow-up (1968-70). 1. The characteristics of the cases notified in 1968. Tubercle (1975) 1.21
Passive smoking. Br J Cancer (1986) 1.19
Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: the UK National Case-Control Study of Cervical Cancer. Br J Cancer (2003) 1.17
AIDS and promiscuity. Lancet (1986) 1.17
Estimating the asbestos-related lung cancer burden from mesothelioma mortality. Br J Cancer (2012) 1.17
Difference between upper and lower limb blood pressure in normal neonates using Doppler technique. Arch Dis Child (1974) 1.16
Projection of mesothelioma mortality in Britain using Bayesian methods. Br J Cancer (2010) 1.11
An assessment of the carcinogenicity of isoniazid in patients with pulmonary tuberculosis. Tubercle (1976) 1.07
Search for tb resonances in proton-proton collisions at √s=7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.07
High-resolution computed tomography of the basilar artery: 1. Normal size and position. AJNR Am J Neuroradiol (1986) 1.06
Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys. Int J Cancer (1996) 1.05
Search for a light Higgs boson decaying to long-lived weakly interacting particles in proton-proton collisions at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.05
Bladder cancer mortality of workers exposed to aromatic amines: analysis of models of carcinogenesis. Br J Cancer (1985) 1.04
Cancer mortality in the first degree relatives of young breast cancer patients. Br J Cancer (1992) 1.04
Treatment of inoperable carcinoma of bronchus. Lancet (1975) 1.04
Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol (2009) 1.03
Analysis of treatment of childhood leukaemia. V. Advantage of reduced chemotherapy during and immediately after cranial irradiation. Br J Cancer (1977) 1.03
An age, period and cohort analysis of pleural cancer mortality in Europe. Eur J Cancer Prev (2000) 1.02
That lung cancer incidence falls in ex-smokers: misconceptions 2. Br J Cancer (2011) 1.01
The incidence of pleural mesothelioma in chrysotile asbestos textile workers. IARC Sci Publ (1980) 1.00
Alcoholics known or unknown to agencies: epidemiological studies in a London suburb. Br J Psychiatry (1973) 0.99
The pattern electroretinogram in optic nerve disease. Ophthalmology (1983) 0.99
A question of morality. Thorax (1978) 0.98
Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis. Clin Otolaryngol Allied Sci (2000) 0.97
Motivation for drinking among men: survey of a London suburb. Psychol Med (1972) 0.97
The role of radiotherapy in treatment of inoperable lung cancer. Int J Radiat Oncol Biol Phys (1977) 0.96
FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. Br J Cancer (2014) 0.96
Secretion of human epidermal growth factor from Saccharomyces cerevisiae using synthetic leader sequences. Gene (1991) 0.95
Respiratory cancer mortality of Welsh nickel refinery workers. IARC Sci Publ (1984) 0.95